Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°áÀå¾Ï¿¡¼­ 5-Fluorouracil-based º¸Á¶Ç×¾ÏÈ­Çпä¹ýÀÇ Ä¡·á¹ÝÀÀ ¿¹ÃøÀÎÀڷνá Á¡¾×¼º ¼±¾ÏÀÇ ÀÇÀÇ Mucinous Histology as a Predictive Marker of 5-Fluorouracil-based Adjuvant Chemotherapy for Colon Cancer

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2009³â 25±Ç 4È£ p.241 ~ 247
°­Á¤Çö, ¹ÚÀ±¾Æ, ¼Õ½Â±¹, ÀÌ°­¿µ, ¹Îº´¼Ò, Á¶Àåȯ, ±è³²±Ô,
¼Ò¼Ó »ó¼¼Á¤º¸
°­Á¤Çö ( Kang Jeong-Hyun ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

¹ÚÀ±¾Æ ( Park Yoon-Ah ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¼Õ½Â±¹ ( Sohn Seung-Kook ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÀÌ°­¿µ ( Rhee Kang-Young ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹Îº´¼Ò ( Min Byung-Soh ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¶Àåȯ ( Cho Jang-Hwan ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è³²±Ô ( Kim Nam-Kyu ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Purpose: The aim of this study was to evaluate the value of mucinous histology as a predictive marker of 5-Fluorouracil (FU)-based adjuvant chemotherapy in stage II, III colon cancer.

Methods: Between January 1995 and December 2004, 987 patients who underwent curative resections for stage II, III sporadic colon cancer were classified into two groups, a mucinous carcinoma (MC) group and a non-mucinous carcinoma (NMC) group, based on the histology of the primary tumor. The differences in their clinicopathological characteristics and the prognostic impact of 5-FU-based adjuvant chemotherapy for various tumor histologies were analyzed.

Results: Of the 987 patients, MCs accounted for 6.8% (68 patients). MCs were more frequently located in the Rt. Colon (P<0.001) and were more frequently seen in young patients (less than 40 yr old) (P=0.028). The 5-yr survival rates between MC and NMC did not show any statistically significant difference. Patients, including both MC and NMC patients, who received 5-FU-based chemotherapy, revealed a better overall survival rate than patients with no adjuvant chemotherapy. In the multivariate analysis for the prognosis in NMC patients, 5-FU-based adjuvant chemotherapy, initial negative nodal status, and preoperative CEA <5 ng/mL were statistically significant prognostic factors (P values: <0.001, <0.001, and <0.001, respectively). In contrast, there was no statistically independent significance of 5-FU-based adjuvant chemotherapy in MC patients.

Conslusion: In stage II and stage III sporadic colon cancer patients, response to 5-FU-based adjuvant chemotherapy in MC patients might be poor than it is in NMC patients.

Å°¿öµå

Á¡¾×¼º ¼±¾Ï;º¸Á¶Ç×¾ÏÈ­Çпä¹ý;°áÀå¾Ï
Mucinous carcinoma;Adjuvant chemotherapy;Colon cancer

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS